文献速递系统性红斑狼疮血管炎

传统心血管危险因素控制对系统性红斑狼疮患者7年随访动脉粥样硬化进展的影响

The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

研究纳入115例SLE患者与1:1年龄性别匹配的健康对照,基线行颈动脉和股动脉超声,7年随访评估新斑块形成。86例SLE患者与42例对照完成随访,SLE患者斑块进展风险约为对照的4倍(OR 4.16),每达标一项ESC可调控CVRF目标,斑块进展风险降低约50%(OR 0.56)。

要点

  • SLE患者7年新发斑块32/86例 vs 对照8/42例(P=0.037)。

核心结论

  • SLE患者动脉粥样硬化斑块进展迅速,而按ESC指南达标可调控心血管危险因素可能大幅减少这一进展。

研究设计与样本

  • 前瞻性超声研究:115例SLE患者与1:1年龄性别匹配的健康对照在心血管研究单元行基线颈动脉和股动脉超声,受邀进行7年随访评估新斑块形成。
  • 最终86例SLE患者和42例对照完成7年随访颈动脉和股动脉斑块检查。

主要发现

  • 新发斑块见于SLE患者32/86例 vs 对照8/42例(P=0.037)。

关键数值与推荐

  • 2022年EULAR关于包括SLE在内的风湿病患者心血管风险管理推荐要求严格管理心血管危险因素(CVRF)。
  • 研究评估的ESC可调控CVRF目标包括血压、吸烟状态、体重、血脂和体力活动。
  • 研究同时评估疾病相关特征:病程、疾病活动度、自身抗体和治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The 2022 EULAR recommendations for cardiovascular risk management in patients with rheumatic disorders, including SLE, call for rigorous management of cardiovascular risk factors (CVRF). The impact of CVRF target attainment on atherosclerotic plaque progression hasn't been previously evaluated in prospective ultrasound studies. METHODS: A total of 115 patients with SLE and 1:1 age and sex-matched healthy controls who had a baseline carotid and femoral ultrasound examination in our cardiovascular research unit were invited for a 7-year follow-up assessment of new plaque development. We aimed to compare the incidence of plaque progression between SLE patients and controls and reveal the extent to which it is affected by the attainment of European Society of Cardiology (ESC) targets for modifiable CVRFs (blood pressure, smoking status, body weight, lipids and physical activity), and disease-related features (disease duration, disease activity, autoantibodies, treatments). RESULTS: Eighty-six SLE patients and 42 controls had a 7-year follow-up carotid and femoral plaque examination. New plaque development was observed in 32/86 patients vs 8/42 controls (P = 0.037). Patients with SLE had a 4-fold higher risk for plaque progression than controls (OR: 4.16, CI: 1.22, 14.19, P = 0.023), adjusting for potential confounders. Multivariate regression analyses showed a 50% decrease in plaque progression for every modifiable CVRF fulfilling ESC targets (OR: 0.56, CI: 0.34, 0.93, P = 0.026). CONCLUSION: Patients with SLE develop a rapid progression of atherosclerotic plaques which may be drastically reduced by CVRF target attainment according to ESC guidelines.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Papazoglou N, Kravvariti E, Konstantonis G, et al. The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus. Rheumatology (Oxford). 2024. PMID: 37086440. doi:10.1093/rheumatology/kead184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。